Literature DB >> 7623820

RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter.

J H Lai1, G Horvath, J Subleski, J Bruder, P Ghosh, T H Tan.   

Abstract

T-cell activation requires two different signals. The T-cell receptor's recognition of a specific antigen on antigen-presenting cells provides one, and the second signal comes from costimulatory molecules such as CD28. In contrast, T cells that are stimulated with antigen in the absence of the CD28 costimulatory signal can become anergic (nonresponsive). The CD28 response element (CD28RE) has been identified as the DNA element mediating interleukin 2 (IL-2) gene activation by CD28 costimulation. Our previous work demonstrates that the Rel/NF-kappa B family proteins c-Rel, RelA (p65), and NFKB1 (p50) are involved in the complex that binds to the CD28RE. We also showed that c-Rel, but not NFKB1 (p50), can bind to the CD28RE and activate CD28RE-driven transcription in cotransfection assays. However, the role of RelA (p65) in CD28 signaling has not yet been addressed. We provide evidence that RelA (p65) itself bound directly to the CD28RE of the IL-2 promoter and other lymphokine promoters. In addition, RelA (p65) was a potent transcriptional activator of the CD28RE in vivo. We show that a RelA (p65)-c-Rel heterodimer bound to the CD28RE and synergistically activated the CD28RE enhancer activity. We also demonstrate that activated Raf-1 kinase synergized with RelA (p65) in activating the CD28RE enhancer activity. Interestingly, a soluble anti-CD28 monoclonal antibody alone, in the absence of other stimuli, also synergized with RelA (p65) in activating the CD28RE. Furthermore, we show that RelA (p65) activated expression of the wild-type IL-2 promoter but not the CD28RE-mutated IL-2 promoter. A combination of RelA (p65) and NFKB1 (p50) also activated the IL-2 promoter through the CD28RE site. These results demonstrate the functional regulation of the CD28RE, within the IL-2 promoter, by Rel/NF-kappa B transcription factors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7623820      PMCID: PMC230665          DOI: 10.1128/MCB.15.8.4260

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  85 in total

1.  The interleukin 2 CD28-responsive complex contains at least three members of the NF kappa B family: c-Rel, p50, and p65.

Authors:  P Ghosh; T H Tan; N R Rice; A Sica; H A Young
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

Review 2.  The role of the CD28 receptor during T cell responses to antigen.

Authors:  P S Linsley; J A Ledbetter
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

3.  Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.

Authors:  C D Gimmi; G J Freeman; J G Gribben; G Gray; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

4.  Rapid activation of C-Raf-1 after stimulation of the T-cell receptor or the muscarinic receptor type 1 in resting T cells.

Authors:  J N Siegel; C H June; H Yamada; U R Rapp; L E Samelson
Journal:  J Immunol       Date:  1993-10-15       Impact factor: 5.422

5.  A novel mode of human immunodeficiency virus type 1 (HIV-1) activation: ligation of CD28 alone induces HIV-1 replication in naturally infected lymphocytes.

Authors:  B Asjö; D Cefai; P Debré; Y Dudoit; B Autran
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  Kappa B site-dependent induction of gene expression by diverse inducers of nuclear factor kappa B requires Raf-1.

Authors:  T S Finco; A S Baldwin
Journal:  J Biol Chem       Date:  1993-08-25       Impact factor: 5.157

7.  Influence of human T-cell leukemia virus type I tax and rex on interleukin-2 gene expression.

Authors:  K L McGuire; V E Curtiss; E L Larson; W A Haseltine
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

8.  T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif.

Authors:  K V Prasad; Y C Cai; M Raab; B Duckworth; L Cantley; S E Shoelson; C E Rudd
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

Review 9.  Signal transduction pathways involving the Raf proto-oncogene.

Authors:  N G Williams; T M Roberts
Journal:  Cancer Metastasis Rev       Date:  1994-03       Impact factor: 9.264

10.  Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function.

Authors:  B Stein; A S Baldwin; D W Ballard; W C Greene; P Angel; P Herrlich
Journal:  EMBO J       Date:  1993-10       Impact factor: 11.598

View more
  29 in total

1.  Interaction of hematopoietic progenitor kinase 1 with adapter proteins Crk and CrkL leads to synergistic activation of c-Jun N-terminal kinase.

Authors:  P Ling; Z Yao; C F Meyer; X S Wang; W Oehrl; S M Feller; T H Tan
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

2.  Costimulation by B7-1 and LFA-3 targets distinct nuclear factors that bind to the interleukin-2 promoter: B7-1 negatively regulates LFA-3-induced NF-AT DNA binding.

Authors:  E Parra; M Varga; G Hedlund; T Kalland; M Dohlsten
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

3.  Opposing roles of serine/threonine kinases MEKK1 and LOK in regulating the CD28 responsive element in T-cells.

Authors:  Li Tao; Scott Wadsworth; Jason Mercer; Cynthia Mueller; Kirsten Lynn; John Siekierka; Avery August
Journal:  Biochem J       Date:  2002-04-01       Impact factor: 3.857

4.  Novel CD28-responsive enhancer activated by CREB/ATF and AP-1 families in the human interleukin-2 receptor alpha-chain locus.

Authors:  J H Yeh; P Lecine; J A Nunes; S Spicuglia; P Ferrier; D Olive; J Imbert
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

5.  CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites.

Authors:  V S Shapiro; K E Truitt; J B Imboden; A Weiss
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

6.  Protein kinase C-theta participates in NF-kappaB activation induced by CD3-CD28 costimulation through selective activation of IkappaB kinase beta.

Authors:  X Lin; A O'Mahony; Y Mu; R Geleziunas; W C Greene
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

7.  Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene.

Authors:  M Mikula; M Schreiber; Z Husak; L Kucerova; J Rüth; R Wieser; K Zatloukal; H Beug; E F Wagner; M Baccarini
Journal:  EMBO J       Date:  2001-04-17       Impact factor: 11.598

8.  Low levels of NF-κB/p65 mark anergic CD4+ T cells and correlate with disease severity in sarcoidosis.

Authors:  Nam-Sihk Lee; Laura Barber; Ali Kanchwala; Carter J H Childs; Yash P Kataria; Marc A Judson; Mark A Mazer; Sergio Arce
Journal:  Clin Vaccine Immunol       Date:  2010-12-22

9.  Protein kinase Calpha (PKCalpha) acts upstream of PKCtheta to activate IkappaB kinase and NF-kappaB in T lymphocytes.

Authors:  Sergey A Trushin; Kevin N Pennington; Eva M Carmona; Susana Asin; Doris N Savoy; Daniel D Billadeau; Carlos V Paya
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

10.  CD25high T cells with a prolonged survival inhibit development of diabetes.

Authors:  Y Yan; Z Xiong; S Zhang; J Song; Y Huang; A M Thornton; H Wang; X-F Yang
Journal:  Int J Immunopathol Pharmacol       Date:  2008 Oct-Dec       Impact factor: 3.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.